COIOSDeep risk insights through multi-disciplinary research across the globe
a city with a river and a tower in the distance
Item new Peer-reviewed Added

Positive airway pressure for sleep apnoea and its five-year persistence in France

Of 84,550 French adults starting positive airway pressure therapy in 2019-2023, 60.5% were still using it at 5 years.

This real-world cohort followed 84,550 adults in France who started positive airway pressure (PAP) therapy in 2019-2023. Provider records with daily PAP data were paired with national claims data for 58,116 patients. Persistence was 83.5% at 1 year, 68.4% at 3 years and 60.5% at 5 years. Higher adherence in the first 4 months went with higher 5-year persistence, in a dose-effect pattern. Mean yearly cost per patient was €5,462, with 28% for hospitalisations and 8% for the PAP device and service. The design was observational with no comparison group, and high 5-year adherence partly reflected early stopping by low users.

Why it is interesting: The study reports PAP persistence over five years using daily device data from a national cohort. Home service provider interventions rose as adherence fell, consistent with the aim of the telemonitoring and pay-for-performance model.

Source
Annals of the American Thoracic Society, 14 November 2026
Paper
Five-Year PAP Persistence, Adherence and Patient Follow-up After Implementation of Telemonitoring and Pay-For-Performance in France
Authors
Baillieul S, Alami S, Prigent A, Bianquis C, Diaz Bazin F, Schaller M et al.
DOI
10.1093/annalsats/aaoag344
Type
Peer-reviewed article
Design
National real-world cohort linking provider daily device records and claims data, 84,550 adults starting PAP 2019-2023, followed to 5 years
Verdict
New finding
Driver
Adherence and persistence
Driver
What linked data reveals
Abstract — the authors' own words, CC BY

Abstract

Rationale

Following an important increase in the number of patients treated with positive airway pressure (PAP) therapy in France, a new nationwide model combining telemonitoring and a pay-for-performance scheme was implemented in 2018.

Objectives

To provide a comprehensive overview of 5-year persistence and adherence to PAP therapy and healthcare utilization after the change in the PAP pathway and model.

Methods

This real-world cohort included adults from France started on PAP in 2019–2023. Data sources included provider records (including daily PAP data) and national claims data. Costs were evaluated from the national payer perspective.

Results

A total of 84,550 patients (63.7% men, mean age 58.5 years, 53.6% with obesity, mean apnea-hypopnea index 40 events/h) were included; 95.7% used telemonitoring. 58,116 patients had paired claims data. PAP therapy persistence was 83.5% at 1 year, 68.4% at 3 years and 60.5% at 5 years. Main documented reasons for stopping PAP were issues with PAP treatment (54.9%), changes in treatment needs (9.3%) and death (7.0%). There was a dose-effect association between PAP adherence in the first 4 months and 5-year persistence. In the first year of treatment, on average, patients consulted with a general practitioner 6.66 times and with another medical specialist 2.53 times; over the same period home service providers delivered 4.0 interventions at home, 3.6 by phone and 2.8 masks. The number of provider interventions (logistic, educational and supportive) increased as adherence decreased. Mean yearly total cost per patient was €5,462: €1,526 (28%) for hospitalizations, €672 (12%) for disability pensions and sick leave benefits, €436 (8%) for the PAP device, consumables and service, and €415 (8%) for medical consultations.

Conclusions

The proportion of adherent patients at 5 years was high, partly driven by the early discontinuation of patients with low adherence. Alongside intensive medical follow-up, HSPs delivered interventions at greater intensity for patients with low adherence, consistent with the objective of the nationwide telemonitoring and pay-for-performance model. However, solutions are needed for patients who have PAP-related issues and to further reduce the therapy termination rate.

Other drivers in Behavioural science